FDA Drug Recalls

11,815 recalls · Class II, newest first

Class II · Moderate risk Terminated Jun 2, 2015

Hydromorphone 0.25 mg/ml Intrathecal Solution

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1540-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hyaluronidase 175 units/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1539-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hyaluronidase 150 units/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1538-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hyaluronidase 150 units/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1537-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hyaluronic Acid Sodium 35 mg/ml + Lidocaine HCl 3 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1536-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hyaluronic Acid Sodium 32 mg/ml + Lidocaine HCl 3 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1535-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hyaluronic Acid Sodium 28 mg/ml + Lidocaine HCl 3 mg/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1534-2015

Class II · Moderate risk Terminated Jun 2, 2015

HCG 500 IU/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1533-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 1

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1532-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 5

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1531-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 4

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1530-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 3

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1529-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 2

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1528-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 1

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1527-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 1

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1526-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 5

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1525-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 11

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1524-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 1

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1523-2015

Class II · Moderate risk Terminated Jun 2, 2015

HCG 625 IU/ml Injection

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1522-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 2

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1521-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 10

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1520-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 1

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1519-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 1

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1518-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 5

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1517-2015

Class II · Moderate risk Terminated Jun 2, 2015

Hcg 5

Reason Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility

The Compounding Pharmacy of America D-1516-2015